Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 17;65(10):e0044321.
doi: 10.1128/AAC.00443-21. Epub 2021 Jul 19.

Irritable Bowel Syndrome Therapeutic Has Broad-Spectrum Antimicrobial Activity

Ashley L Cunningham  1 , Orhi Esarte Palomero  1 , Bradley J Voss  2 , M Stephen Trent  2   3 , Bryan W Davies  1
Affiliations

Irritable Bowel Syndrome Therapeutic Has Broad-Spectrum Antimicrobial Activity

Ashley L Cunningham et al. Antimicrob Agents Chemother. .

Abstract

Otilonium bromide is a poorly absorbed oral medication used to control irritable bowel syndrome. It is thought to act as a muscle relaxant in the intestine. Here, we show that otilonium bromide has broad-spectrum antibacterial and antifungal activity, including against multidrug-resistant strains. Our results suggest otilonium bromide acts on enteric pathogens and may offer a new scaffold for poorly absorbed intestinal antimicrobial therapy.

Keywords: antibacterial; antifungal; otilonium bromide.

PubMed Disclaimer

Figures

FIG 1
FIG 1
(A) Structure of OB (top), salicylanilide (blue), and general quaternary amine biocide (red). Counter ions have been excluded for clarity. Related structures are color matched. (B and C) Time-kill curve of untreated or 0.5×, 1×, and 2× OB MIC-treated E. coli H10407 (B) and S. aureus USA100 635 (C). Cultures were serially diluted and spotted to determine viable numbers of CFU/ml at the indicated time points. Plots show the means and standard errors of the means from 6 biological replicates. The limit of detection was 102 CFU/ml.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Clavé P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, Tack J, OBIS Study Investigators. 2011. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther 34:432–442. 10.1111/j.1365-2036.2011.04730.x. - DOI - PubMed
    1. Clavé P, Tack J. 2017. Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis. Ther Adv Gastroenterol 10:311–322. 10.1177/1756283X16681708. - DOI - PMC - PubMed
    1. Evangelista S, Traini C, Vannucchi MG. 2018. Otilonium bromide: a drug with a complex mechanism of action. Curr Pharm Des 24:1772–1779. 10.2174/1381612824666180507122935. - DOI - PubMed
    1. Forte E, Pizzoferrato M, Lopetuso L, Scaldaferri F. 2012. The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide. Eur Rev Med Pharmacol Sci 16:25–37. - PubMed
    1. Sutton JA, Kilminster SG, Mould GP. 1997. The clinical pharmacology of single doses of otilonium bromide in healthy volunteers. Eur J Clin Pharmacol 52:365–369. 10.1007/s002280050302. - DOI - PubMed

Publication types

Substances

LinkOut - more resources